| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3155069b833b184bcd4ad12f7100dd4c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_87d38c1b9165abcc3314333971d83b08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e1b99cefecf31da7b7ef78efff114e2f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-172
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10T436-143333 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4045
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-404
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P19-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2008-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2015-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0d38eac6a26e07a197fe7a177e4c3995
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a0b7b7f5dbc730e2fbdcea2e5691c480 |
| publicationDate |
2015-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9062347-B2 |
| titleOfInvention |
Endothelin single nucleotide polymorphisms and methods of predicting β-adrenergic receptor targeting agent efficacy |
| abstract |
The present invention concerns the use of methods for evaluating β-adrenergic receptor targeting agent treatment for a patient, particularly one with a heart condition. In general, the disclosed methods entail determining the presence or absence of one or more polymorphisms in an endothelin gene system member. Based on the results of this determination, a β-adrenergic receptor targeting agent may be prescribed, administered or a treatment regimen altered, including the administration of a β-blocker. Accordingly, methods of treatment are also described. |
| priorityDate |
2007-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |